axsome teva - Search News

Teva, Axsome and patent infringement

FiercePharma · 3d

Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press release. Entrance of the generic will be delayed by an additional six months, until March 31, 2039, if Axsome gains an FDA pediatric exclusivity extension for its treatment.

Business Insider · 3d

Shares in Biopharma Firm Axsome Surge Over 20% After Settling Teva Patent Dispute

Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute with peer Teva

BioPharma Dive · 3d

Axsome secures top drug’s future with Teva patent settlement

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy of Auvelity from entering the U.S. market until at least 2038.

3d

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The ...

2d

Why Axsome Therapeutics Stock Is Soaring Today

Shares of Axsome Therapeutics ( AXSM -0.49%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results